PubMed Health⌕ Search

PubMed · 16401339

MIAME/Plant - adding value to plant microarrray experiments.

Abstract

Appropriate biological interpretation of microarray data calls for relevant experimental annotation. The widely accepted MIAME guidelines provide a generic, organism-independant standard for minimal information about microarray experiments. In its overall structure, MIAME is very general and specifications cover mostly technical aspects, while relevant organism-specific information useful to understand the underlying experiments is largely missing. If plant biologists want to use results from published microarray experiments, they need detailed information about biological aspects, such as growth conditions, harvesting time or harvested organ(s). Here, we propose MIAME/Plant, a standard describing which biological details to be captured for describing microarray experiments involving plants. We expect that a more detailed and more systematic annotation of microarray experiments will greatly increase the use of transcriptome data sets for the scientific community. The power and value of systematic annotation of microarray data is convincingly demonstrated by data warehouses such as Genevestigator(R) or NASCArrays, and better experimental annotation will make these applications even more powerful.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Philip Zimmermann, Beatrice Schildknecht, David Craigon, Margarita Garcia-Hernandez, Wilhelm Gruissem, Sean May, Gaurab Mukherjee, Helen Parkinson, Seung Rhee, Ulrich Wagner, Lars Hennig. 2006-01-09. MIAME/Plant - adding value to plant microarrray experiments.. https://doi.org/10.1186/1746-4811-2-1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.

Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.

Editorial↗